Stocks Health care EMBC
NASDAQ · Health careEmbecta Corp. (EMBC)
Embecta Corp. brought in $1B of revenue over the twelve months to June 30, 2026, down 7.6% from a year earlier. Net income was $87.5M, a net margin of 8.6%. Operating cash flow minus capital spending left $182.4M of free cash flow in fiscal 2025. At June 30, 2026 it held $214.7M in cash against $1.5B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about Embecta Corp.
- Net worth
- Embecta Corp. has a market value (market cap) of $363.2M at the latest share price, and shareholders' equity of -$612.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.1B (-3.8% year on year), with net income of $95.4M. Over the 12 months to June 30, 2026: revenue $1B, net income $87.5M.
- Cash flow
- In fiscal 2025 operations brought in $191.7M of cash; after $9.3M of capital spending, free cash flow was $182.4M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Embecta Corp.'s next report is expected around November 24, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Embecta Corp. declared dividends of $0.60 per share in fiscal 2025, a yield of 9.36% at the current price.
What Embecta Corp. does
Embecta Corp. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker EMBC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.1B | $95.4M | $1.62 | $182.4M |
| 2024 | $1.1B | $78.3M | $1.34 | $19.9M |
| 2023 | $1.1B | $70.4M | $1.22 | $41.2M |
| 2022 | $1.1B | $223.6M | $3.89 | $388.6M |
| 2022 | $1.2B | $414.8M | $7.28 | $419.5M |
| 2020 | $1.1B | $427.6M | $7.50 | $456.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where EMBC ranks in Health care
Dividends
Embecta Corp. declared $0.60 per share in fiscal 2025. At the current price that is a yield of 9.36%. It paid out $35M in cash dividends, 37% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.60 | $35M | 37% |
| 2024 | $0.60 | $34.5M | 44% |
| 2023 | $0.60 | $34.4M | 49% |
| 2022 | $0.15 | $8.6M | 4% |
| 2022 | n/a | $0 | 0% |
| 2020 | n/a | $0 | 0% |
Latest SEC filings
What Embecta Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 8.1% to $271.7M versus the same quarter last year; diluted EPS $0.36 versus $0.78.
- August 7, 2026
- July 31, 2026Exhibits 8-K/A
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- May 27, 2026Passive stake changed SCHEDULE 13G/A
- May 22, 2026
- May 15, 2026
- May 5, 2026Passive stake (5% or more) SCHEDULE 13G
What is EMBC worth? A DCF from its reported cash flow
Insider trades
What the people running Embecta Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $37K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 4, 2026 | Morris Milton MayoDirector | Sold | 6,293 | $37K |
| August 12, 2026 | Hombach Robert J.Director | Bought | 45,000 | $223.8K |
| August 12, 2026 | Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLO | Bought | 20,000 | $99.8K |
| August 12, 2026 | Elguicze JacobSVP and CFO | Bought | 20,000 | $93.4K |
| August 12, 2026 | Kurdikar DevdattPresident and CEO, Director | Bought | 30,000 | $140.9K |
| August 9, 2026 | Casner JeanChief Human Resources Officer | Shares withheld for tax | 1,480 | $6.5K |
| June 1, 2026 | Roth Anthony M.VP, Chief Accounting Officer | Received as pay | 30,000 | - |
| February 11, 2026 | Reidy Christopher RDirector | Received as pay | 22,841 | - |
Who owns EMBC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Yacktman Asset Management LP13G, passive with 1 related filers | 6.2% | May 5, 2026 |
| Vanguard Capital Management13G, passive | 5.07% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 320 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 4,599,771 | -4,567,441 |
| Yacktman Asset Management LP | 4,315,952 | +644,075 |
| Vanguard Capital Management LLC | 2,557,148 | -6,803 |
| Deerfield Management Company, L.P. | 2,534,961 | 0 |
| Jefferies Financial Group Inc. | 2,355,117 | -45 |
| Ameriprise Financial Inc | 2,038,731 | +1,239,043 |
| Morgan Stanley | 1,996,747 | +1,386,943 |
| State Street Corp | 1,610,666 | -935,307 |
| Geode Capital Management, LLC | 1,594,457 | +128,810 |
| Brigade Capital Management, LP | 1,516,453 | new |
| Goldman Sachs Group Inc | 1,162,041 | +413,586 |
| Vanguard Portfolio Management LLC | 1,098,389 | -439,568 |
| Charles Schwab Investment Management Inc | 1,069,786 | -122,247 |
| Jacobs Levy Equity Management, Inc | 1,027,514 | new |
| Aqr Capital Management LLC | 976,587 | +644,984 |
| Millennium Management LLC | 945,968 | -648,177 |
| UBS Group AG | 829,099 | +399,049 |
| D. E. Shaw & Co., Inc. | 650,070 | +117,742 |
| Royce & Associates LP | 639,378 | +575,818 |
| Bank of New York Mellon Corp | 581,480 | -242,307 |
Insiders
12 insiders reported holding 2,065,871 shares in total, about $13.2M at the last price.
| Holder | Shares |
|---|---|
| Kurdikar DevdattPresident and CEO, Director | 804,919 |
| Elguicze JacobSVP and CFO | 309,139 |
| Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLO | 262,915 |
| Hombach Robert J.Director | 109,587 |
| Curtis ShaunSVP, Global Manuf./Sup. Chain | 95,324 |
| Casner JeanChief Human Resources Officer | 85,915 |
| Roth Anthony M.VP, Chief Accounting Officer | 78,833 |
| Reidy Christopher RDirector | 70,122 |
| Pomeroy ClaireDirector | 66,127 |
| Anderson Carrie LDirector | 64,581 |
Questions about EMBC
What does Embecta Corp. do?
Embecta Corp. is a company in the Health care sector, listed on NASDAQ as EMBC. Its shares trade on NASDAQ under the ticker EMBC.
What is Embecta Corp.'s net worth?
Embecta Corp. has a market value (market cap) of $363.2M at the latest share price, and shareholders' equity of -$612.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Embecta Corp. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $87.5M on revenue of $1B, a net margin of 8.6%.
How much revenue does Embecta Corp. make?
Over the twelve months to June 30, 2026 Embecta Corp. reported revenue of $1B. That is 7.6% less than a year earlier.
When did Embecta Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 8, 2026.
When is Embecta Corp.'s next earnings report?
Embecta Corp.'s next report is expected around November 24, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Embecta Corp. pay a dividend?
Yes. Embecta Corp. declared dividends of $0.60 per share in fiscal 2025, a yield of 9.36% at the current price.
Similar companies
Compare EMBC with
Follow EMBC
Get an email when Embecta Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Embecta Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.